Analysis: The peptide problem: Hype is outrunning the evidence McMaster News BPC 157: Separating Fact from Fiction in Soft Tissue Injury Treatment Erik Schraga posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica